Duke Street Bio Ltd. has divulged poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.

Scientists at St. John’s University, The University of Pennsylvania and Université de Montréal have identified poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the ...

[48–50] Final data remain to be published. Table 1. Poly-(ADP-ribose) polymerase inhibitors in clinical studies. PARP inhibitor Number of completed or ongoing studies Type of studies completed ...

Results from the PAOLA-1 study showed that the PARP inhibitor drug significantly increased the time women lived without disease progression when added to the standard-of-care, Genentech’s ...

Mutations in BRCA2—a gene known to repair damaged DNA and suppress tumor formation—can predict an individual's predisposition ...

which would really broaden the use of PARP inhibitors.” The phase 1 PETRA trial of AZD5305 has already begun in solid tumours and O’Connor said the drug will likely be used in cancers with ...

LAE120 is a novel, allosteric and highly potent USP1 inhibitor, displaying monotherapy potency and combination activity with PARP inhibitor ... ovarian cancer and PD-1/ PD-L1 drug-resistant ...

Maintenance with niraparib and bevacizumab can be effective in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a PARP inhibitor.

Mutations in BRCA2 — a gene known to repair damaged DNA and suppress tumor formation — can predict an individuals' predisposition to develop breast cancer, ovarian, prostate, pancreatic, and other ...